Home >> Pharmaceuticals >> Food & Beverage >>

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015

Published: Jul-2015 | Format: PDF | Global Markets Direct | Number of pages: 47 | Code: MRS - 31593

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015’, provides an overview of the Nasopharyngitis (Common Cold)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Nasopharyngitis (Common Cold) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nasopharyngitis (Common Cold) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngitis (Common Cold) Overview 7
Therapeutics Development 8
Pipeline Products for Nasopharyngitis (Common Cold) - Overview 8
Pipeline Products for Nasopharyngitis (Common Cold) - Comparative Analysis 9
Nasopharyngitis (Common Cold) - Therapeutics under Development by Companies 10
Nasopharyngitis (Common Cold) - Therapeutics under Investigation by Universities/Institutes 11
Nasopharyngitis (Common Cold) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Nasopharyngitis (Common Cold) - Products under Development by Companies 15
Nasopharyngitis (Common Cold) - Products under Investigation by Universities/Institutes 16
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development 17
Charleston Laboratories, Inc. 17
Cocrystal Pharma, Inc. 18
Neos Therapeutics, Inc. 19
Orbis Biosciences, Inc. 20
Vernalis Plc 21
Nasopharyngitis (Common Cold) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 31
(chlorpheniramine maleate + codeine) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CCP-05 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCP-06 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CCP-07 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CCP-08 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CLAT-313 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
guaifenesin ER - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule for Cough and Cold - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Nasopharyngitis (Common Cold) - Recent Pipeline Updates 42
Nasopharyngitis (Common Cold) - Dormant Projects 43
Nasopharyngitis (Common Cold) - Discontinued Products 44
Nasopharyngitis (Common Cold) - Product Development Milestones 45
Featured News & Press Releases 45
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing 45
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2015 8
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories, Inc., H2 2015 17
Nasopharyngitis (Common Cold) - Pipeline by Cocrystal Pharma, Inc., H2 2015 18
Nasopharyngitis (Common Cold) - Pipeline by Neos Therapeutics, Inc., H2 2015 19
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences, Inc., H2 2015 20
Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Assessment by Combination Products, H2 2015 23
Number of Products by Stage and Target, H2 2015 25
Number of Products by Stage and Mechanism of Action, H2 2015 27
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Nasopharyngitis (Common Cold) Therapeutics - Recent Pipeline Updates, H2 2015 42
Nasopharyngitis (Common Cold) - Dormant Projects, H2 2015 43
Nasopharyngitis (Common Cold) - Discontinued Products, H2 2015 44

List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2015 8
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Top 10 Targets, H2 2015 24
Number of Products by Stage and Top 10 Targets, H2 2015 24
Number of Products by Top 10 Mechanism of Actions, H2 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 28
Number of Products by Top 10 Molecule Types, H2 2015 29
Number of Products by Stage and Top 10 Molecule Types, H2 2015 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2000 View Pricing